Scarica l'app Stockscreener
28.02
0.07%
0.02
Dopo l'orario di chiusura:
28.05
0.03
+0.11%
Precedente Chiudi:
$28.00
Aprire:
$28.95
Volume 24 ore:
633.11K
Relative Volume:
0.78
Capitalizzazione di mercato:
$2.65B
Reddito:
-
Utile/perdita netta:
$-115.88M
Rapporto P/E:
-18.11
EPS:
-1.5468
Flusso di cassa netto:
$-104.72M
1 W Prestazione:
-0.99%
1M Prestazione:
+4.94%
6M Prestazione:
+64.53%
1 anno Prestazione:
+57.15%
Intervallo 1D:
$27.76
$28.95
Intervallo di 1 settimana:
$27.01
$29.81
Portata 52W:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Confronta EWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
28.02 | 2.65B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpWhat's Next? - MarketBeat
Moody Aldrich Partners LLC Has $5.02 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Edgewise Therapeutics names new COO - MSN
Edgewise Therapeutics reshuffles executive team - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.1%Here's What Happened - MarketBeat
Edgewise elevates chief operating officer, hires development exec - BizWest
Edgewise Therapeutics Promotes Behrad Derakhshan, Ph.D., to Chief Operating Officer Role - Defense World
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? - Insider Monkey
New COOs for Vividion, Edgewise - BioCentury
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownWhat's Next? - MarketBeat
Edgewise Therapeutics names new COO By Investing.com - Investing.com Australia
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - BioSpace
Edgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan
Edgewise stock rated as a new Hold at Stifel (EWTX:NASDAQ) - Seeking Alpha
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target By Investing.com - Investing.com Canada
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Update - MarketBeat
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Should You Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - BioSpace
How To Trade (EWTX) - Stock Traders Daily
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $2,737,000.00 in Stock - MarketBeat
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock - Investing.com India
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data (NASDAQ:EWTX) - Seeking Alpha
Franklin Resources Inc. Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):